Introduction
Aspergillus fumigatus is widespread in the environment and is the main Aspergillus species responsible for human diseases in both immunocompromised and immunocompetent hosts. Inherently resistant to fluconazole, A. fumigatus is usually susceptible to the other triazole antifungal drugs, such as itraconazole, voriconazole or posaconazole, and voriconazole is the first-line therapy for invasive aspergillosis. Since the first two published cases in 1997, 1 an ever-growing number of studies focusing on acquired azole resistance in both clinical and environmental A. fumigatus isolates suggest that azole resistance is increasing.
2,3 Azole resistance mainly results from substitutions in lanosterol 14a-demethylase (encoded by the cyp51A gene). 4 In the Netherlands, the main mechanism involves a 34 bp tandem repeat in the promoter region of the cyp51A gene along with a leucine to histidine substitution at residue 98 (also referred to as TR/L98H), which confers multiazole resistance. 3 The main hypothesis explaining why TR/L98H is found in .90% of A. fumigatus azole-resistant isolates from the Netherlands relies on the widespread use of azole compounds in agriculture. 5, 6 Outside the Netherlands, isolates with Although TR/L98H has also been recently reported in France, there are limited data regarding its prevalence in this country. 10, 11 Here, we present the results of a 16 month retrospective study to determine the frequency and molecular mechanisms of azole resistance in a cohort of patients with cystic fibrosis (CF).
Patients and methods
One hundred and forty-two sputum and bronchial aspiration samples (mean number of samples per patient¼2.8; 1 -18 samples per patient) from 50 CF patients (mean age¼21 years; 5 -46 years of age) admitted to the Pneumology Department of Nantes University Hospital (France) during January 2010 to April 2011 were analysed retrospectively. Ninety-seven of the 142 (68.3%) samples were positive for A. fumigatus. Twenty-six patients (52%) had several positive samples (two to six samples). Eighty-five of the 97 isolates (12 unavailable for analysis) were included in this study.
Azole resistance was screened by subculturing each isolate on agar plates containing 4 mg/L itraconazole. Plates were prepared in-house and contained RPMI 1640 medium (Sigma-Aldrich, Saint-Quentin Fallavier, France) supplemented with 2% D-glucose (Sigma-Aldrich) buffered with 3-(N-morpholino)propanesulphonic acid (MOPS; 0.165 M final concentration, Sigma-Aldrich) at pH 7.0 and 1.5% Bacto agar (Difco, Pont de Claix, France). Briefly, fresh conidia from a 7-day-old culture on Sabouraud dextrose agar slants with chloramphenicol (bioMérieux, Marcy l'Étoile, France) were suspended in sterile water at a turbidity equivalent to that of a 0.5 McFarland standard. Plates were inoculated by dipping a sterile swab into the inoculum suspension and swabbing the entire agar surface. Plates were then incubated at 358C for 72 h. Two Aspergillus ustus isolates were included as positive controls in each set of experiments. Itraconazole resistance was evaluated by Etest w (AB Biodisk, bioMérieux, France) for each isolate that was able to grow on azole-containing agar plates. MICs of itraconazole, voriconazole and posaconazole were therefore determined by the reference microdilution method according to EUCAST (CNRMA, Institut Pasteur, Paris, France). 12 Isolates with MICs .2 mg/L were considered resistant to itraconazole 13 and voriconazole, 4 and isolates with MICs .0.25 mg/L were considered resistant to posaconazole. 14 Species identification of itraconazole-resistant isolates was performed by amplification and sequencing of the b-tubulin gene. 15 Each of these isolates was further subjected to the amplification and sequencing of the cyp51A gene, as described previously, 10 and of a 234 bp region of its promoter using the primers AFTR-F (5 ′ -TAATCGCAGCACCACTTCAG-3 ′ ) and AFTR-R (5 ′ -GCCTAGGACAAGGACGAATG-3 ′ ). Nucleotide sequences were compared with the reference sequence of the A. fumigatus azolesusceptible strain CM-237 (GenBank accession number AF338659). Genotyping of the itraconazole-resistant isolates was performed using four microsatellite markers with a global discriminatory power of 0.994, as described previously. 16 Briefly, amplification was carried out in a 20 mL reaction mixture containing 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 0.1 mM each dNTP, 0.1 mM each primer (Sigma, Paris, France) and 1 U of Amplitaq Gold Taq DNA polymerase (Applied Biosystems, Meylan, France). After an initial denaturation step at 948C for 5 min, samples were amplified by 30 cycles of denaturation at 948C for 30 s, annealing at 598C for 30 s and elongation at 728C for 30 s, and then a final extension at 728C for 30 min. Next, 2 mL of the PCR product was mixed with 13 mL of HiDi Formamide (Applied Biosystems) containing 0.5 mL of 6-carboxy-X-rhodamine-labelled Geneflo 625 size standard (Eurx, Gdansk, Poland). Capillary electrophoresis was performed using the ABI Prism 3730XL sequencer and allele sizes were calculated with GeneMapper software (version 4; Applied Biosystems). Since the four microsatellite markers consist of dinucleotide repeats, the alleles were considered to be different when a 2 bp difference was observed.
Results and discussion
Nine of the 85 isolates (four patients, 8% global prevalence) were able to grow on itraconazole-containing agar (Table 1) (Table 1) . Importantly, five out of the nine isolates, coming from three patients (Patients 1, 2 and 3, Table 1 ), displayed multiazole resistance (resistance to itraconazole, voriconazole and posaconazole). Previous exposure to mould-active azoles (mostly itraconazole) was recorded for each of these patients.
To provide further insight into the mechanisms responsible for azole resistance in these isolates, we amplified the cyp51A coding sequence and its promoter. The nine itraconazoleresistant isolates displayed mutations in the cyp51A gene at residues previously linked to azole resistance: L98H (n¼ 5), M220T (n¼ 4) and G54R (n ¼1) ( Table 1 ). All isolates with L98H also displayed the 34 bp tandem repeat (TR/L98H) and were recovered from three patients (6% global prevalence in CF). As expected, isolates with TR/L98H displayed multiazole resistance. 4 Patient 3 had three A. fumigatus isolates with distinct azole resistance mechanisms on three separate samplings. Compared with TR/L98H, M220T was associated with itraconazole resistance, but lower MICs of voriconazole. Combination of M220T with G54R was associated with resistance to posaconazole, but voriconazole retained significant in vitro activity (MIC¼ 0.25 mg/L).
Overall, whereas the acquisition of TR/L98H in Patients 1, 2 and 3 can hardly be excluded from having arisen from long-term azole therapy (as none of these patients was 'azole naive'), the main hypothesis is that these patients were contaminated by A. fumigatus itraconazole-resistant isolates from their environment. 5 This hypothesis is supported by microsatellite typing data, as Patients 1, 2 and 3 displayed almost identical TR/L98H genotypes (Table 1) . In stark contrast, other isolates (including itraconazole-susceptible isolates from these patients) had completely different genotypes (Table 1) .
One interesting finding is the description of Patient 1, who was colonized for 11 months by a unique itraconazole-resistant A. fumigatus isolate with TR/L98H upon genotyping. Such chronic colonization by a multiazole-resistant isolate in the course of CF, also reported in another study, 8 must be considered in antifungal management strategies after lung transplantation. However, our study also illustrates that colonization of the respiratory tract by A. fumigatus in the course of CF is a complex and dynamic process, as illustrated here by: (i) the recovery of multiple azole-resistant isolates from a single patient (Patient 3); and (ii) the recovery of itraconazole-susceptible isolates before (Patient 4) or after the recovery of itraconazoleresistant isolates (Patient 3).
In previous studies, the prevalence of itraconazole resistance was ,1%, 4.5% and 4.6% in Portugal, 17 Denmark 8 and France, Triazole resistance in Aspergillus fumigatus 1871 JAC respectively. 11 Here, we report a high prevalence of itraconazole resistance in A. fumigatus isolated from CF patients at our centre (4/50 patients, 8%). Importantly, TR/L98H was the main mechanism responsible for azole resistance in our study (3/50 patients, 6%), confirming that TR/L98H is prevalent in France. 5, 11 Of note, TR/L98H was not reported in the single study focusing on patients with haematological malignancies in France, 10 providing evidence that the prevalence of TR/L98H and more generally azole resistance varies from centre to centre and probably also according to the underlying diseases. 18 Indeed, azole resistance has been especially described in CF and in patients with chronic pulmonary aspergillosis or allergic bronchopulmonary aspergillosis, with a prevalence rate as high as 75%. 19 On the other hand, azole resistance has been shown to be lower but highly variable in patients with haematological malignancies, with prevalence rates varying from 0.01% to 9.4%. 10, 18 As already shown, itraconazole-containing plates are easy to use in a routine mycology laboratory, offering the possibility of screening large collections of clinical strains at low cost. 8 However, the use of a concentration of 4 mg/L itraconazole, which has also been reported by others 8, 9, 18 but is above the susceptibility breakpoint for A. fumigatus (≤1 mg/L), 13 might be a limitation of our study as some non-susceptible isolates could have been missed.
In summary, the present study highlights a high prevalence of itraconazole resistance in A. fumigatus, mostly driven by TR/L98H, in CF patients at our centre. From a more global perspective, nationwide and multicentre surveys involving medical centres responsible for the management of patients at high risk of invasive aspergillosis, such as those with CF, are urgently needed to evaluate the burden of azole resistance in A. fumigatus. Morio et al.
